Suchergebnisse - "van der Heijde, Désirée"

PubPharm (64)

1

Bimekizumab treatment in patients with active axial spondyloarthritis : 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies

enthalten in: Annals of the rheumatic diseases | 2024

von Baraliakos, X. | Deodhar, A. | van der Heijde, D. | +11

2

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis : study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial

enthalten in: Trials | 2023

von Ritchlin, C. | Coates, L. | Mease, P. | +6

3

Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis

enthalten in: Arthritis research & therapy | 2022

von Mease, P. | van der Heijde, D. | Kirkham, B. | +8

4

Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis : Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study

enthalten in: Arthritis & rheumatology (Hoboken, N.J.) | 2022

von Baraliakos, X. | Deodhar, A. | Dougados, M. | +12

CommentIn: Nat Rev Rheumatol. 2022 Sep;18(9):494. - PMID 35922551

5

Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years

enthalten in: The Journal of rheumatology | 2022

von van der Heijde, D. | Østergaard, M. | Reveille, J. | +7

6

Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled Trial

enthalten in: Arthritis care & research | 2022

von Walsh, J. | Magrey, M. | Baraliakos, X. | +14

7

Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years : Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis

enthalten in: Arthritis & rheumatology (Hoboken, N.J.) | 2022

von McInnes, I. | Rahman, P. | Gottlieb, A. | +9

8

Tofacitinib for the treatment of ankylosing spondylitis : a phase III, randomised, double-blind, placebo-controlled study

enthalten in: Annals of the rheumatic diseases | 2021

von Deodhar, A. | Sliwinska-Stanczyk, P. | Xu, H. | +11

9

Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis : 2-year (end-of-study) results from the FUTURE 5 study

enthalten in: RMD open | 2021

von Mease, P. | Landewé, R. | Rahman, P. | +9

10

Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis

enthalten in: Arthritis & rheumatology (Hoboken, N.J.) | 2021

von McInnes, I. | Rahman, P. | Gottlieb, A. | +12

1
2
3
4
5
6
7
Nächster »
[7]